Pharmafile Logo

GE

- PMLiVE

Johnson & Johnson’s multiple myeloma treatment approved by US FDA

The approval was based on phase 3 data showing survival rates of 83.3% after three years

- PMLiVE

Gilead Foundation announces $12m investment through HIV Prevention Initiative

The US state investment will go to 33 community-based organisations

- PMLiVE

Webinar: What do HCPs really want from pharma digital in 2026?

Our research shows that healthcare professionals are not disengaging from pharma digital. They are becoming more selective about the experiences that earn their attention. To explore what this means for...

Graphite Digital

Intelligent field team engagement: Turning shared knowledge into deeper insights and better decisions.

At Age of AI 2026, Inizio Medical’s Phil Wakefield and Inizio Ignite’s Tim Luxford will explore how cross-functional collaboration and AI can unlock faster, more actionable insights across medical and...

Inizio

- PMLiVE

GenAI: embracing the transformation – with caution

Despite the GenAI fervour, there is an acute need to prepare organisations to understand which specific tools they need and how to use them

- PMLiVE

AI in practice: 4 real-world use cases in health and life sciences

Artificial Intelligence (AI) is often discussed in broad terms, with promises of transformation at scale. In practice, however, its value is realized in far more specific ways – when it...

Inizio

- PMLiVE

CNX Therapeutics appoints Erin Federman as non-executive director

Federman previously held roles at Novo Nordisk and Mylan

- PMLiVE

A Pharma Brand Manager’s Guide to Exhibiting

Securing your exhibition space is a significant milestone. The contract is signed, the floorplan is confirmed and the event is in the calendar. So what happens next? Exhibiting successfully involves...

Apex Events and Exhibitions

- PMLiVE

J&J’s nipocalimab gets FDA Fast Track designation for lupus

The autoimmune disease affects approximately three to five million people globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links